Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
1. To determine the outcome of patients with potentially resectable superior sulcus tumors of non-small cell histology treated by surgery followed by accelerated radiation therapy and chemotherapy. 2. To evaluate toxicity, the initial local-regional control rate, sites of and time to local and distant failures.
Checked against the public recordLast updated Jun 30, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Interventions being studied
- Procedure: Surgery; Radiation: Chest Irradiation; Drug: Cisplatin; Drug: Etoposide; Radiation: Prophylactic Cranial Irradiation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. No previous treatment. 2. Tumor must be resectable. 3. \>/= 18 and \</= 70 years of age. 4. Zubrod performance status \</= or higher performance status if based only on pain. 5. Must have adequate bone marrow, liver and renal function as defined in 3.6. Exclusion Criteria: 1. Cytological or histological proof of N3 disease. 2. Evidence of metastatic disease to distant sites. 3. Patients with impending cord compression will be ineligible.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Texas MD Anderson Cancer CenterHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 30, 2016. Always confirm current availability with the study team.